Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Bioventus Inc.
  6. Company
    BVS   US09075A1088

BIOVENTUS INC.

(BVS)
  Report
Delayed Quote. Delayed Nasdaq - 08/02 04:00:00 pm
14.8 USD   -5.07%
07/30MISONIX : Bioventus to Acquire Misonix in Cash-and-Stock Deal Valued at $518 Million
MT
07/30Top Midday Gainers
MT
07/29BIOVENTUS : VOTING AND SUPPORT AGREEMENT (Form 8-K)
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Bioventus Inc is a global medical device company. The Company is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone. The minimally invasive fracture treatment offers its Exogen system for the non-invasive treatment of established nonunion fractures and certain fresh fractures.

Number of employees : 700 people.
Sales per Business
20192020Delta
Osteoathritis Joint Pain Treatment and Joint Preservation182.0853.5%171.1853.3% -5.99%
Minimally Invasive Fracture Treatment103.5030.4%88.6227.6% -14.38%
Bone Graft Substitutes54.5616%61.3619.1% +12.47%
USD in Million
Sales per region
20192020Delta
United States305.0789.7%293.7091.4% -3.73%
International35.0710.3%27.468.6% -21.69%
USD in Million
Managers
Name Title Age Since
Kenneth Michael Reali Chief Executive Officer & Director 54 2020
Gregory O. Anglum Chief Financial Officer & Senior Vice President 50 -
Miguel O. Beltrán-Delgado Senior Vice President-Operations - 2021
Mary Kay Ladone Independent Director 54 2021
John Ernest Nosenzo Chief Commercial Officer - 2017
Alessandra Pavesio Chief Science Officer & Senior Vice President - -
Anthony D Adamio Senior Vice President & General Counsel - -
Members of the board
Name Title Age Since
William A. Hawkins Chairman 66 -
Guido J. Neels Director 71 2016
Guy Paul Nohra Director 59 2016
Dave J. Parker Director - 2016
Martin P. Sutter Director 65 2016
Bradley J. Cannon Director 52 -
Philip G. Cowdy Director 53 -
Kenneth Michael Reali Chief Executive Officer & Director 54 2020
Susan M. Stalnecker Director 67 -
Mary Kay Ladone Independent Director 54 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 56,825,326 28,061,545 49.4% 0 0.0% 38.6%
Stock B 1 15,786,737 0 0.0% 0 0.0%
Shareholders
NameEquities%
Essex Woodlands Management, Inc. 12,096,702 29.5%
Smith & Nephew plc 6,229,991 15.2%
Spindletop Healthcare Capital LP 3,906,395 9.52%
Ampersand Management LLC 3,255,332 7.93%
Genesis Investment Management LLP 2,821,283 6.87%
Alta Partners Management Corp. 2,604,264 6.35%
Millennium Management LLC 2,161,024 5.27%
Redmile Group LLC 1,500,000 3.66%
Avidity Partners Management LP 1,254,333 3.06%
Deerfield Management Company LP 957,000 2.33%
Company contact information
Bioventus, Inc.
4721 Emperor Boulevard
Suite 100
Durham, NC 27703

Phone : +1.919.474.6700